Cancer Therapy & Research Center
7979 Wurzbach Rd., San Antonio, TX 78229 (210) 450-1000
Toll free: 1-800-340-CTRC (2872)
Toll free: 1-800-340-CTRC (2872)
| Establishing Community-Based Urinary Biomarkers: A Study on Prostate Screening and Detection | |||
|---|---|---|---|
| Principal Investigator: Dr. Ian Thompson Jr., MD | IRB #: HSC-2002-0380H | ||
| Department Address, Main Campus |
|
||
| Contact Person:
SABOR Team |
|||
Enrollment Notes: Men only |
|||
| The target age is: | No age limitation | ||
Study Begin and End Date: September 2002-ongoing |
|||
Eligibility Criteria: Men who have been diagnosed with prostate cancer. |
|||
Type of Study: Observational |
|||
| Funding Source: NCI through the Early Detection Research Network | |||
| Detailed description of this study | |||
This research study has been ongoing for 10 years and originally funded by the American Cancer Society. For the past 3 years it has been funded by the National Cancer institute but with a different focus. The three goals of this study are:
|
|||
| Establishing Community-Based Urinary Biomarkers: A Study on Prostate Screening and Detection | |||
|---|---|---|---|
| Principal Investigator: Dr. Ian Thompson Jr., MD | IRB #: HSC-2011-0312H | ||
| Department Address, Main Campus |
|
||
| Contact Person:
SABOR Team |
|||
Enrollment Notes: Men only |
|||
| The target age is: | Men ages 40-79 | ||
Study Begin and End Date: September 2011-September 2013 |
|||
Eligibility Criteria: Men ages 40-79 who are interested in a prostate screening exam and do not have a history of prostate cancer, prostate surgery or a prostate biopsy. |
|||
Type of Study: Community Based Screening |
|||
| Funding Source: NCI through the Early Detection Research Network | |||
| Detailed description of this study | |||
This research study is focused on expanding our knowledge of a biomarker for prostate cancer called PCA3, a molecule found in the prostate gland. The goal of this study is to evaluate this new biomarker in normal prostate cancer screening. PSA (prostate specific antigen) screening and a digital rectal exam (DRE), to check for growths or enlargement of the prostate, will be provided at no cost. Participants will be asked to attend 1 visit with physicians and research staff as well as provide annual follow up information over the phone for up to 5 years. Procedures will take approximately 1 hour and written PSA results will be sent to you, and if you request, to your provider. |
|||
| San Antonio Center of Biomarkers of Risk for Prostate Cancer | |||
|---|---|---|---|
| Principal Investigator: Dr. Ian Thompson Jr., MD | IRB #: HSC-2000-0030H | ||
| Department Address, Main Campus |
|
||
| Contact Person:
SABOR Team |
|||
Enrollment Notes: Men ages 35 and above |
|||
| The target age is: | Recommended age 45 | ||
Study Begin and End Date: January 2000- ongoing |
|||
Eligibility Criteria: Men ages 35 and above who are interested in PSA screening and have not been diagnosed with prostate cancer. |
|||
Type of Study: Screening Cohort |
|||
| Funding Source: NCI through the Early Detection Research Network | |||
| Detailed description of this study | |||
The San Antonio Center of Biomarkers of Risk for Prostate Cancer (SABOR), is a long-term research study of a large group of men that will help researchers improve the detection of prostate cancer. The program provides annual PSA (Prostate Specific Antigen) screening at no cost. Subjects participating in this study will be asked to attend one visit per year for PSA screening and complete annual follow-up phone interviews. Written PSA results will be provided to you, and if you request, to your provider. |
|||
| Improving Prostate Biopsy Efficiency: The Finasteride Challenge | |||
|---|---|---|---|
| Chief investigator: Dr. Ian Thompson, MD | IRB #: HSC-2010-0352H | ||
| Department of Urology, 7703 Floyd Curl Drive, San Antonio, TX 78229 |
|
||
| You may contact Esther Nanez, RN at 210-567-1995 or nanez@uthscsa.edu. | |||
| Only male subjects are needed for this study. | |||
| The target age is: | 55 years and older | ||
| This study begins 2/1/2011 and is scheduled to end 9/30/2015 | |||
Eligibility Criteria: Men at risk of prostate cancer who are considering a prostate biopsy with an elevated PSA. |
|||
| The type of this study is: | |||
| Intervention Study | |||
| Funding Source: National Institutes of Health (NIH) | |||
| Detailed description of this study | |||
| Randomized, Placebo-controlled, Double Blind study to improve prostate cancer screening with PSA using a 3-month treatment of Finasteride vs. placebo | |||
| Identification of Protein and Genetic Biomarkers of Prostate Cancer and Risk Factors for Progression of Disease | |||
|---|---|---|---|
| Chief investigator: Dr. Ian Thompson, MD | IRB #: HSC-20020-380H | ||
| Department of Urology, 7703 Floyd Curl Drive, San Antonio, TX 78229 |
|
||
| You may contact Brandi Weaver at 210-567-0178 or weaverb@uthscsa.edu | |||
| Only male subjects are needed for this study. | |||
| The target age is: | |||
| 19 - 64 years | |||
| 64 years and older | |||
| This study is in progress and has no scheduled date of completion. | |||
| Eligibility Criteria: For men with a previous diagnosis of prostate cancer. | |||
| Funding Source: National Cancer Institute | |||
| Detailed description of this study | |||
| The purpose of this study is to identify genetic variants that predict progression of prostate cancer. | |||
CFG920 is a non-steroidal, reversible dual inhibitor of CYP17 and CYP11B2 with potential antiandrogen and antineoplastic activities. In this Phase I/II study CFG920 will be administered orally in patients with metastatic castration-resistant prostate cancer after progressing (or have refused) on Abiraterone and Docetaxel.
Title: Phase III randomized study to compare the early chemotherapy with Docetaxel plus androgen ablation to androgen ablation alone in prostate cancer patients with extensive disease.
Metformin is widely used anti-diabetic medicine. It can also act as an anti-cancer agent by activation of AMP-activated protein kinase (AMPK) pathway and subsequent inhibition of mTOR that blocks the cancer cell growth and proliferation. It may also lessen the symptoms of metabolic syndrome caused by androgen deprivation therapy. In this Phase II study patients with advanced prostate cancer will be randomly selected to receive castration only or castration plus metformin as first line treatment.
For veterans only; Patients will take Nexrutine® (an oral dietary supplement) prior to and during radiation treatment for prostate cancer or prior to surgery for prostate cancer. The purpose of the study is to see whether taking Nexrutine® will cause the PSA (Prostate Specific Antigen) to decline.
